Repligen (RGEN) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $184.17, +3.35% vs the prior close of $178.20.
- Volume 1.04M shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RGEN jumps 3.4% to $184.17, 3 up days in a row. Closed at $184.17, +3.35% vs the prior close of $178.20. Day range $177.49–$185.99, opened at $178.28.
RGEN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — RGEN jumps 3.4% to $184.17, 3 up days in a row
- Closed at $184.17, +3.35% vs the prior close of $178.20. Day range $177.49–$185.99, opened at $178.28.
- Volume was 1.04M shares, 0.9x its 50-day average of 1.12M.
- Price is +5.0% vs its 50-day average ($175.46) and +27.8% vs its 200-day average ($144.08).
- 52-week range $100.99–$198.87; today's close sits at 85% of that range, 7.4% below the 52-week high.
- That makes 3 straight gains.
Oct 14, 2026 — RGEN rises 1.6% to $178.20
- Closed at $178.20, +1.58% vs the prior close of $175.42. Day range $175.39–$181.07, opened at $175.42.
- Volume was 1.22M shares, 1.1x its 50-day average of 1.12M.
- Price is +1.9% vs its 50-day average ($174.95) and +23.8% vs its 200-day average ($143.99).
- 52-week range $100.99–$198.87; today's close sits at 79% of that range, 10.4% below the 52-week high.
Oct 13, 2026 — RGEN rises 1.7% to $175.42
- Closed at $175.42, +1.69% vs the prior close of $172.51. Day range $169.73–$177.96, opened at $172.51.
- Volume was 1.26M shares, 1.1x its 50-day average of 1.12M.
- Price is +0.6% vs its 50-day average ($174.38) and +21.9% vs its 200-day average ($143.93).
- 52-week range $100.99–$198.87; today's close sits at 76% of that range, 11.8% below the 52-week high.
Oct 12, 2026 — RGEN dips 0.8% to $172.51
- Closed at $172.51, -0.79% vs the prior close of $173.88. Day range $169.90–$173.82, opened at $171.73.
- Volume was 899.60K shares, 0.8x its 50-day average of 1.12M.
- Price is -0.8% vs its 50-day average ($173.82) and +19.9% vs its 200-day average ($143.88).
- 52-week range $100.99–$198.87; today's close sits at 73% of that range, 13.3% below the 52-week high.
Oct 9, 2026 — RGEN jumps 6.1% to $173.88
- Closed at $173.88, +6.13% vs the prior close of $163.84. Day range $164.21–$174.82, opened at $164.21.
- Volume was 1.34M shares, 1.2x its 50-day average of 1.11M.
- Price is +0.4% vs its 50-day average ($173.19) and +20.9% vs its 200-day average ($143.85).
- 52-week range $100.99–$198.87; today's close sits at 74% of that range, 12.6% below the 52-week high.
Oct 8, 2026 — RGEN dips 2.0% to $163.84, a 1-month low, 3 down days in a row
- Closed at $163.84, -2.02% vs the prior close of $167.22. Day range $157.44–$164.65, opened at $164.00.
- Volume was 1.23M shares, 1.1x its 50-day average of 1.12M.
- Price is -5.1% vs its 50-day average ($172.58) and +13.9% vs its 200-day average ($143.81).
- 52-week range $100.99–$198.87; today's close sits at 64% of that range, 17.6% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — RGEN slides 4.4% to $167.22 on 2.4x normal volume
- Closed at $167.22, -4.37% vs the prior close of $174.86. Day range $165.99–$175.04, opened at $174.75.
- Volume was 2.63M shares, 2.4x its 50-day average of 1.12M — unusually heavy trading.
- Price is -2.9% vs its 50-day average ($172.13) and +16.3% vs its 200-day average ($143.80).
- 52-week range $100.99–$198.87; today's close sits at 68% of that range, 15.9% below the 52-week high.
Oct 6, 2026 — RGEN slides 7.7% to $174.86
- Closed at $174.86, -7.73% vs the prior close of $189.50. Day range $174.36–$194.36, opened at $191.90.
- Volume was 1.70M shares, 1.5x its 50-day average of 1.11M.
- Price is +1.8% vs its 50-day average ($171.69) and +21.6% vs its 200-day average ($143.75).
- 52-week range $100.99–$198.87; today's close sits at 75% of that range, 12.1% below the 52-week high.
- SEC filings that day: 8-K.
Oct 5, 2026 — RGEN jumps 4.3% to $189.50
- Closed at $189.50, +4.29% vs the prior close of $181.70. Day range $178.61–$191.26, opened at $178.75.
- Volume was 1.61M shares, 1.5x its 50-day average of 1.11M.
- Price is +10.9% vs its 50-day average ($170.82) and +31.9% vs its 200-day average ($143.66).
- 52-week range $100.99–$198.87; today's close sits at 90% of that range, 4.7% below the 52-week high.
Oct 2, 2026 — RGEN rises 2.5% to $181.70
- Closed at $181.70, +2.52% vs the prior close of $177.23. Day range $178.00–$186.52, opened at $179.32.
- Volume was 1.46M shares, 1.3x its 50-day average of 1.13M.
- Price is +7.1% vs its 50-day average ($169.67) and +26.6% vs its 200-day average ($143.51).
- 52-week range $100.99–$198.87; today's close sits at 82% of that range, 8.6% below the 52-week high.
RGEN latest news & SEC filings
Every SEC filing by or about RGEN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 8, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Douglass Brian Robb received an award of 700 shares on Oct 6, 2026; now holds 8,685
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 6, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Loeillot Olivier sold 1,333 shares at $178.75 (≈$238.27K) on Oct 5, 2026; now holds 45,788
- Loeillot Olivier converted options/RSUs into 4,202 shares at $154.96 (≈$651.14K) on Oct 5, 2026; now holds 49,990
- Loeillot Olivier sold 4,202 shares at $190.00 (≈$798.38K) on Oct 5, 2026; now holds 45,788
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.01 — Completed an acquisition or sale of assets.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Oct 5, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 5, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Loeillot Olivier had withheld for taxes 1,248 shares at $181.70 (≈$226.76K) on Oct 2, 2026; now holds 47,121
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 28, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Garland Jason K had withheld for taxes 421 shares at $189.68 (≈$79.86K) on Sep 25, 2026; now holds 18,408
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 15, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 8, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 4, 2026 · 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade RGEN
- Last results release: Jul 28, 2026 (8-K Item 2.02). Previous ones: Jul 22, 2026, May 5, 2026, Feb 24, 2026. Based on that rhythm, the next report is likely around Oct 27, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.86% (largest 7.8%).
- Liquidity: about 1.36M shares (≈$250.41M) trade per day on average.
- 52-week position: $184.17 vs a range of $100.99–$198.87 (85% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 23 sales; latest: Olivier Loeillot sold 8,404 shares on Sep 24, 2026.
- Latest filings: 8-K Oct 6, 2026; 8-K Sep 15, 2026; 8-K Sep 8, 2026.
- Share count: 56.44M shares outstanding (Jul 24, 2026), +0.3% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
RGEN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 178.28 | 185.99 | 177.49 | 184.17 | 1.04M |
| Oct 14, 2026 | 175.42 | 181.07 | 175.39 | 178.20 | 1.22M |
| Oct 13, 2026 | 172.51 | 177.96 | 169.73 | 175.42 | 1.26M |
| Oct 12, 2026 | 171.73 | 173.82 | 169.90 | 172.51 | 899.60K |
| Oct 9, 2026 | 164.21 | 174.82 | 164.21 | 173.88 | 1.34M |
| Oct 8, 2026 | 164.00 | 164.65 | 157.44 | 163.84 | 1.23M |
| Oct 7, 2026 | 174.75 | 175.04 | 165.99 | 167.22 | 2.63M |
| Oct 6, 2026 | 191.90 | 194.36 | 174.36 | 174.86 | 1.70M |
| Oct 5, 2026 | 178.75 | 191.26 | 178.61 | 189.50 | 1.61M |
| Oct 2, 2026 | 179.32 | 186.52 | 178.00 | 181.70 | 1.46M |
| Oct 1, 2026 | 194.00 | 194.00 | 177.12 | 177.23 | 1.95M |
| Sep 30, 2026 | 193.09 | 195.61 | 190.97 | 192.23 | 730.40K |
| Sep 29, 2026 | 196.00 | 196.65 | 190.98 | 194.57 | 1.14M |
| Sep 28, 2026 | 187.25 | 198.87 | 187.11 | 194.09 | 1.57M |
| Sep 25, 2026 | 189.92 | 191.51 | 186.91 | 189.68 | 1.50M |
| Sep 24, 2026 | 184.10 | 192.49 | 183.75 | 190.65 | 1.60M |
| Sep 23, 2026 | 186.38 | 188.95 | 181.71 | 184.53 | 934.80K |
| Sep 22, 2026 | 180.72 | 188.20 | 180.00 | 186.75 | 1.16M |
| Sep 21, 2026 | 176.89 | 182.25 | 176.22 | 180.71 | 857.60K |
| Sep 18, 2026 | 179.10 | 179.10 | 176.29 | 176.89 | 1.36M |
About Repligen
Repligen (RGEN) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in WALTHAM, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 730272.
RGEN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Nicolas Barthelemy | Director | May 18, 2026 |
| Karen A Dawes | Director | May 18, 2026 |
| Manner Carrie Eglinton | Director | May 18, 2026 |
| Anthony Hunt | Director | Mar 3, 2026 |
| Konstantin Konstantinov | Director | May 18, 2026 |
| Olivier Loeillot | Chief Executive Officer | Sep 25, 2026 |
| Glenn P Muir | Director | May 18, 2026 |
| Martin D Madaus | Director | May 18, 2026 |
| Rohin Mhatre | Director | May 18, 2026 |
| Margaret Pax | Director | May 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| James Bylund | Chief Operating Officer | Mar 23, 2026 |
| Brian Robb Douglass | CHIEF PRODUCT OFFICER | May 8, 2026 |
| Jason K Garland | CFO | Sep 28, 2026 |
| Violetta Hughes | CHIEF ACCOUNTING OFFICER | Sep 2, 2026 |
| Ralf Kuriyel | Senior VP, R&D | Mar 23, 2026 |
| Olivier Loeillot | Chief Executive Officer | Sep 25, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 24, 2026 | Olivier Loeillot | Sale | 8,404 | $190.00 |
| Sep 24, 2026 | Olivier Loeillot | Sale | 4,542 | $190.00 |
| Sep 21, 2026 | Olivier Loeillot | Sale | 5,426 | $180.00 |
| Sep 4, 2026 | Olivier Loeillot | Sale | 3,035 | $165.90 |
| Aug 20, 2026 | Olivier Loeillot | Sale | 5,426 | $180.00 |
| Jul 16, 2026 | Jason K Garland | Sale | 530 | $150.00 |
| Jun 25, 2026 | Jason K Garland | Sale | 733 | $145.00 |
| Apr 21, 2026 | Olivier Loeillot | Sale | 3,832 | $140.00 |
| Dec 17, 2025 | Karen A Dawes | Sale | 275 | $161.00 |
| Nov 25, 2025 | Olivier Loeillot | Sale | 7,041 | $170.00 |
| Nov 18, 2025 | James Bylund | Sale | 2,191 | $151.21 |
| Nov 13, 2025 | Anthony Hunt | Sale | 1,784 | $151.01 |
| Nov 13, 2025 | Anthony Hunt | Sale | 2,100 | $152.17 |
| Nov 13, 2025 | Anthony Hunt | Sale | 2,923 | $153.14 |
| Nov 13, 2025 | Anthony Hunt | Sale | 2,500 | $154.32 |
RGEN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $48.89M | 0.86 | $117.42M |
| Dec 31, 2024 | — | $-25.51M | -0.46 | $175.39M |
| Dec 31, 2023 | — | $35.60M | 0.63 | $113.92M |
| Dec 31, 2022 | — | $185.96M | 3.24 | $172.08M |
| Dec 31, 2021 | — | $128.29M | 2.24 | $119.02M |
Latest balance sheet: total assets $2.95B, total liabilities $838.15M, cash $606.78M (as of Jun 30, 2026).
RGEN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 28, 2026 | 8-K Item 2.02 (results) | $145.34 |
| Jul 22, 2026 | 8-K Item 2.02 (results) | $140.09 |
| May 5, 2026 | 8-K Item 2.02 (results) | $125.61 |
| Feb 24, 2026 | 8-K Item 2.02 (results) | $134.67 |
| Oct 28, 2025 | 8-K Item 2.02 (results) | $151.57 |
| Jul 29, 2025 | 8-K Item 2.02 (results) | $125.30 |
| Apr 29, 2025 | 8-K Item 2.02 (results) | $139.43 |
| Feb 20, 2025 | 8-K Item 2.02 (results) | $162.67 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $148.59 |
| Sep 18, 2024 | 8-K Item 2.02 (results) | — |
| Jul 30, 2024 | 8-K Item 2.02 (results) | — |
| May 1, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on RGEN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.